Pragma Biosciences, founded with the mission to find cures for undruggable immunological disorders, leverages synthetic biology and real-world data. The company focuses on mapping multi-omic signatures linked to clinical outcomes to produce microbial-derived small molecules with therapeutic potential. Their AI-enabled, biology-first approach targets the gut-immune axis, aiming to revolutionize drug discovery by overcoming the limitations of traditional target-first methods and synthetic molecule libraries.

Notable affiliated individuals and investors in Pragma Biosciences include experts in synthetic biology and immunology, although specific names are not disclosed. The company has achieved significant milestones in identifying novel small molecules with clinical relevance, positioning itself as a pioneer in the field. Pragma Biosciences' innovative approach has the potential to significantly impact the treatment landscape for complex immunological disorders, offering new hope for conditions previously deemed undruggable.